Autopsy report · NCT03961815
Open-label Extension Study of Brazikumab in Crohn's Disease
Cause of deathFunding or business
“Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.”
Life of this trial
- Registered 8 months before it started.
- Ran for about 3 years 8 months before it stopped.
- 18 participants enrolled.
- Results were posted on the registry 2 years 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Crohn's Disease; IBD
- Interventions
- Brazikumab Induction Dose; Brazikumab Maintenance Dose
- Participants
- 18
- Sites
- 15
- Countries
- Germany, Poland, South Africa, Taiwan, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.